NCT03326921
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 38 versions: 31 with changes below, 7 re-verified with no change. See every version on ClinicalTrials.gov ↗
Stopped Recruitment suspended Sponsor's reason: On recruitment pause for administrative reason (funding) Show 4 more changesShow less
- Eligibility criteria expanded, about 19 words
- Secondary endpoints: details revised at 5 of 9 entries
- Site details revised
- Publications: details revised at 1 of 1 entry
- Notable Eligibility criteria shortened, about 6 words
- Interventions: CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR (Biological), Laboratory Biomarker Analysis (Other) to Biospecimen Collection (Procedure), Bone Marrow Aspiration (Procedure), CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR…
- Secondary endpoints revised (9)
- Notable Trial status: Suspended to Recruiting
- Study description expanded, about 12 words
- Site details revised
- Minor Interventions: CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR (Biological), Fludarabine (Drug), Laboratory Biomarker Analysis (Other) to CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR (Biological), Laboratory Biomarker Analysis (Other)
- Study description expanded, about 18 words
- Collaborators: 1 to 2
- Stopped Trial status: Recruiting to Suspended Sponsor's reason: Pause in funding
- Site details revised
Show 25 earlier versionsHide 25 earlier versions
- Notable Trial status: Suspended to Recruiting
- Site details revised
- Notable Primary completion date: Oct 16, 2024 to Oct 16, 2027
- Study completion date: Jul 16, 2025 to Jul 16, 2028
- Notable Eligibility criteria shortened, about 58 wordsv27
- Stopped Trial status: Recruiting to Suspended Sponsor's reason: Pause in funding
- Site details revised
- Minor Collaborators: 4 to 1v24
- Minor Site contact updatedv22
- Notable Eligibility criteria expanded, about 58 wordsv21
- Notable Eligibility criteria expanded, about 5 words
- Study description shortened, about 151 words
- Notable Primary completion date: Dec 16, 2023 to Oct 16, 2024
- Study completion date: Oct 16, 2024 to Jul 16, 2025
- Notable Eligibility criteria shortened, about 56 words
- Study description revised
- Minor Collaborators: 3 to 4
- Study title revised
- Study description shortened, about 1 word
- Notable Trial status: Suspended to Recruiting
- Site details revised
- Stopped Trial status: Recruiting to Suspended Sponsor's reason: COVID19 Suspension
- Site details revised
- Notable Trial status: Suspended to Recruiting
- Site details revised
- Stopped Trial status: Recruiting to Suspended Sponsor's reason: COVID19 Suspension
- Site details revised
- Notable Primary completion date: Dec 16, 2019 to Dec 16, 2023
- Study completion date: Oct 16, 2020 to Oct 16, 2024
- Notable Eligibility criteria expanded, about 18 words
- Interventions: CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR (Biological), Fludarabine Phosphate (Drug), Laboratory Biomarker Analysis… to CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR (Biological), Fludarabine (Drug), Laboratory Biomarker Analysis (Other)
- Minor Site contact updatedv9
- Notable Eligibility criteria expanded, about 9 words
- Study description shortened, about 1 word
- Notable Start date: Dec 14, 2017 to Feb 23, 2018
- Eligibility criteria shortened, about 322 words
- Secondary endpoints: details revised at 2 of 9 entries
- Study description revised
- Minor Start date changed from estimate of Jun 23, 2018 to Dec 14, 2017v6
- Notable Start date: Apr 23, 2018 to Jun 23, 2018v5
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date: Mar 1, 2018 to Apr 23, 2018
- Secondary endpoints: details revised at 1 of 9 entries
- Site details revised
Notable Start date: Jan 1, 2018 to Mar 1, 2018v3 Show 5 more changesShow less
- Eligibility criteria expanded, about 61 words
- Interventions: Fludarabine Phosphate (Drug), Immunotherapy (Biological), Laboratory Biomarker Analysis (Other) to CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR (Biological), Fludarabine Phosphate (Drug), Laboratory Biomarker Analysis…
- Secondary endpoints revised (9)
- Study description revised
- Collaborators reordered
- Notable Start date: Nov 1, 2017 to Jan 1, 2018v2
- Study First Submitted
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Feasibility of manufacturing minor H antigen (HA-1) T cell receptor (TCR) CD8+ and CD4+ T cells
Timeframe: At time of T cell infusion (at day 0)
Feasibility of administering minor H antigen (HA-1) T cell receptor (TCR) CD8+ and CD4+ T cells
Timeframe: At time of T cell infusion (at day 0)
Incidence of dose-limiting toxicities of HA-1 T cell receptor (TCR) T cells
Timeframe: Up to 12 weeks after T-cell infusion
Secondary (9)
Duration of in vivo persistence of transferred HA-1 T cell receptor (TCR) CD4+ T cells in peripheral blood
Duration of in vivo persistence of transferred HA-1 T cell receptor (TCR) CD8+ T cells in peripheral blood
Presence, proportion and persistence of HA-1 T cell receptor (TCR) CD4+ T cells in the bone marrow
Presence, proportion and persistence of HA-1 T cell receptor (TCR) CD8+ T cells in the bone marrow
Specific cytolytic activity of HA-1 T cell receptor (TCR) CD8+ and CD4+ T cells against HLA-A*0201+ HA-1+ target cells before adoptive T cell transfer
Show 4 moreShow less
Specific cytolytic activity of HA-1 T cell receptor (TCR) CD8+ and CD4+ T cells against HLA-A*0201+ HA-1+ target cells after adoptive T cell transfer
Reduction of leukemia in the bone marrow in subjects who have measurable leukemia in the marrow prior to HA-1 T cell receptor (TCR) T cell infusion
Reduction of recipient normal hematopoietic cells in the bone marrow in subjects who have measurable recipient normal hematopoietic cells in the marrow prior to HA-1 T cell receptor (TCR) T cell infusion
Proportion of subjects who develop new or recurrent symptoms or signs of graft-versus-host disease
Arms and interventions
Treatment (CD4+ and CD8+ HA-1 TCR T cells)Experimental
Patients receive lymphodepleting chemotherapy (e.g., fludarabine and cyclophosphamide or debulking regimens as specified in the protocol) ending 2-14 days prior to HA-1 TCR T cell administration. Patients then receive CD4+ and CD8+ HA-1 TCR T cells IV.
Biologicals: CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR
Procedures: Bone Marrow Aspiration, Biospecimen Collection
Sites
1 site in 1 country
- Fred Hutch/University of Washington Cancer ConsortiumSeattle, Washington, United States